Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Fertility Preservation: Recent Developments and New Insights
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Fertility Preservation: Recent Developments and New Insights

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 13722

Special Issue Editors

Dr. Jennifer L. Eaton

E-Mail Website
Guest Editor
Women and Infants Hospital, Brown University, Providence, RI, USA
Interests: reproductive endocrinology and infertility; fertility preservation; in vitro fertilization; assisted reproductive technology
Dr. David B. Seifer

E-Mail Website
Guest Editor
Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine, 333 Cedar St, New Haven, CT 06510, USA
Interests: reproductive aging; AMH; racial disparities in IVF; fertility preservation; in vitro fertilization; assisted reproductive technology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Since the birth of Louise Brown in 1978, assisted reproductive technology (ART) has become a mainstay of fertility treatment.  Numerous technological advances have yielded improved success rates and enabled patients to cryopreserve gametes and embryos for future use.

Historically, fertility preservation was only routinely recommended for patients at an increased risk of infertility due to treatment with chemotherapeutic agents, radiation, or surgery.  Improvements in outcomes have subsequently resulted in the lifting of experimental labels from oocyte cryopreservation and ovarian tissue cryopreservation. As such, fertility preservation has become more accessible to patients who are not yet ready to build their families but are at risk of future infertility due to reproductive aging. Fertility preservation has also been increasingly utilized for patients prior to testosterone therapy and gender-affirming surgery.

A growing body of literature supports the safety and efficacy of fertility preservation in certain patient populations.  For example, live birth rates with cryopreserved oocytes in young women are comparable to those with fresh oocytes. Data on the efficacy of ovarian tissue cryopreservation are promising, although still relatively sparse.

Given the increased utilization and rapid technological progress in the field of fertility preservation, the topic is ripe for study. This Special Issue focuses on recent developments and new insights in fertility preservation.

Dr. Jennifer L. Eaton
Dr. David B. Seifer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fertility preservation
  • oocyte cryopreservation
  • in vitro fertilization
  • assisted reproductive technology
  • ovarian tissue cryopreservation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 253 KiB  
Article
Identification of Psychological Profiles of Cancer Patients Undergoing Fertility Preservation Counseling
by Valentina Elisabetta Di Mattei, Paola Taranto, Gaia Perego, Serena Desimone, Paola Maria Vittoria Rancoita, Antonio Catarinella, Raffaella Cioffi, Giorgia Mangili, Valeria Stella Vanni and Massimo Candiani
J. Clin. Med. 2023, 12(12), 4011; https://doi.org/10.3390/jcm12124011 - 12 Jun 2023
Viewed by 1999
Abstract
Gonadotoxicity is one of the most distressing side effects of cancer treatment. Fertility preservation strategies should be included during the treatment pathway to prevent the risk of infertility, but the decision to preserve fertility often represents a challenging process that carries an emotional [...] Read more.
Gonadotoxicity is one of the most distressing side effects of cancer treatment. Fertility preservation strategies should be included during the treatment pathway to prevent the risk of infertility, but the decision to preserve fertility often represents a challenging process that carries an emotional decision-making burden. The aim of this study is to characterize the psychological profiles of women undergoing fertility preservation counseling and to better understand their features. Eighty-two female cancer patients were included in the study. They were asked to complete a battery of self-administered tests which evaluated socio-demographic characteristics, defense mechanisms, depression, anxiety, and representations regarding the importance of parenthood. Based on the psychometric variables, cluster analysis identified four groups which showed significantly different combinations of these psychological characteristics. An additional analysis was performed to evaluate if sociodemographic variables were associated with the four groups, but the results did not show significant differences. These results suggest that very diverse psychological profiles may lead cancer patients to attend oncofertility counseling and choose fertility preservation. For this reason, all patients in childbearing age should have the opportunity to receive appropriate fertility preservation counseling in order to make an informed decision that could have an important impact on their long-term quality of life. Full article
(This article belongs to the Special Issue Fertility Preservation: Recent Developments and New Insights)

Review

Jump to: Research

12 pages, 586 KiB  
Review
Exploring the Frontiers of Ovarian Tissue Cryopreservation: A Review
by Tia Ramirez and MaryEllen Pavone
J. Clin. Med. 2024, 13(15), 4513; https://doi.org/10.3390/jcm13154513 - 2 Aug 2024
Cited by 4 | Viewed by 2440
Abstract
Objective: This paper serves as an up-to-date narrative review of the most effective methods and outcomes of ovarian tissue cryopreservation (OTC) with new data comparing this method to oocyte and embryo cryopreservation as well as its utility in restoration of endocrine function. [...] Read more.
Objective: This paper serves as an up-to-date narrative review of the most effective methods and outcomes of ovarian tissue cryopreservation (OTC) with new data comparing this method to oocyte and embryo cryopreservation as well as its utility in restoration of endocrine function. Background: Data on OTC are becoming more available as more patients are achieving cancer remission and choosing to use their cryopreserved tissue to conceive or restore endocrine function. With OTC only recently becoming a non-experimental method of fertility preservation, it is important to evaluate, compare, and optimize current practices to improve live birth outcomes. Methods: A literature search of meta-analyses, systematic reviews, case series, retrospective studies, and randomized control trials was performed using the PubMed database with multiple search terms. Discussion: Current practices and outcomes of OTC remain heterogeneous, though they are becoming more streamlined with the emerging data on successful live births. Multiple aspects of OTC have been studied to optimize protocols, particularly methods of cryopreserving, in vitro maturation, and transplantation. In vitro follicle maturation is a novel application with emerging data on methods and outcomes. OTC is a versatile method not only for fertility preservation but also for hormone restoration as well. With wider usage of OTC, ethical dilemmas will need to be addressed. Conclusions: OTC can be used as fertility preservation for a variety of patients. Recent studies suggest it may be comparable to embryo cryopreservation, but with growing data on live births, comparative studies should continue to be performed. In vitro follicle maturation (IVFM) is a promising application of ovarian tissue harvesting. Data are lacking on cost-effectiveness, patient satisfaction, and morbidity associated with OTC. Full article
(This article belongs to the Special Issue Fertility Preservation: Recent Developments and New Insights)
►▼ Show Figures

Figure 1

13 pages, 249 KiB  
Review
A Review of Animal Models Investigating the Reproductive Effects of Gender-Affirming Hormone Therapy
by Nicholas S. Raja, Elizabeth S. Rubin and Molly B. Moravek
J. Clin. Med. 2024, 13(4), 1183; https://doi.org/10.3390/jcm13041183 - 19 Feb 2024
Cited by 4 | Viewed by 3467
Abstract
Gender-affirming hormone therapy (GAHT) is an important component in the process of transitioning for many transgender and gender-diverse (TGD) individuals. Multiple medical organizations recommend fertility preservation counseling prior to initiation of GAHT; however, there remains little high-quality data regarding the impact of GAHT [...] Read more.
Gender-affirming hormone therapy (GAHT) is an important component in the process of transitioning for many transgender and gender-diverse (TGD) individuals. Multiple medical organizations recommend fertility preservation counseling prior to initiation of GAHT; however, there remains little high-quality data regarding the impact of GAHT on fertility and reproductive function. A PubMed literature review was performed using Boolean search operators linking keywords or phrases such as “mouse”, “rat”, “primate”, “animal model”, “transgender”, “gender”, “estrogen”, “testosterone”, “fertility”, and “fertility preservation”. Recent research has produced a number of animal models of GAHT that utilize similar hormonal regimens and produce similar phenotypic results to those used and observed in human patients. Specific to testosterone(T)-containing GAHT, animals demonstrate loss of menstrual cyclicity with therapy, resumption of menses on cessation of therapy, suppression of gonadotropin levels, and physical changes such as clitoromegaly. Models mimicking GAHT for transmasculine individuals in the peripubertal period demonstrate that pretreatment with GnRHa therapy does not modify the effects of subsequent T administration, which were similar to those described in adult models. Both models suggest promising potential for future fertility with cessation of T. With estradiol (E)-containing GAHT, animals exhibit decreased size of testicles, epididymis, and seminal vesicles, as well as ongoing production of spermatocytes, and seminiferous tubule vacuolization. Given the ethical challenges of conducting human studies in this area, high-fidelity animal models represent a promising opportunity for investigation and could eventually transform clinical counseling about the necessity of fertility preservation. Future studies should better delineate the interactions (if any exist) between treatment attributes such as dosing and duration with the extent of reversibility of reproductive perturbations. The development of models of peripubertal feminizing GAHT is an additional area for future work. Full article
(This article belongs to the Special Issue Fertility Preservation: Recent Developments and New Insights)
15 pages, 513 KiB  
Review
Oocyte Cryopreservation for Medical and Planned Indications: A Practical Guide and Overview
by Eric Han and David B. Seifer
J. Clin. Med. 2023, 12(10), 3542; https://doi.org/10.3390/jcm12103542 - 18 May 2023
Cited by 8 | Viewed by 4689
Abstract
Oocyte cryopreservation (OC) is the process in which ovarian follicles are stimulated, the follicular fluid is retrieved, and mature oocytes are isolated and vitrified. Since the first successful pregnancy utilizing previously cryopreserved oocytes in 1986, OC has become increasingly utilized as an option [...] Read more.
Oocyte cryopreservation (OC) is the process in which ovarian follicles are stimulated, the follicular fluid is retrieved, and mature oocytes are isolated and vitrified. Since the first successful pregnancy utilizing previously cryopreserved oocytes in 1986, OC has become increasingly utilized as an option for future biologic children in patients facing gonadotoxic therapies, such as for the treatment of cancer. Planned OC, also termed elective OC, is growing in popularity as a means to circumvent age-related fertility decline. In this narrative review, we describe both medically indicated and planned OC, focusing on the physiology of ovarian follicular loss, OC technique and risks, timing of when OC should be performed, associated financial considerations, and outcomes. Full article
(This article belongs to the Special Issue Fertility Preservation: Recent Developments and New Insights)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop